Germline mutations in the PAF1 complex gene CTR9 predispose to Wilms tumour.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 25099282.
- Also identified by DOI 10.1038/ncomms5398 and PMC identifier 4143912.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Wilms tumour is a childhood kidney cancer. Here we identify inactivating CTR9 mutations in 3 of 35 Wilms tumour families, through exome and Sanger sequencing. By contrast, no similar mutations are present in 1,000 population controls (P<0.0001). Each mutation segregates with Wilms tumour in the family and a second mutational event is present in available tumours. CTR9 is a key component of the polymerase-associated factor 1 complex which has multiple roles in RNA polymerase II regulation and is implicated in embryonic organogenesis and maintenance of embryonic stem cell pluripotency. These data establish CTR9 as a Wilms tumour predisposition gene and suggest it acts as a tumour suppressor gene.
Medical subject headings
- Genetic Predisposition to Disease
- Germ-Line Mutation
- Nuclear Proteins
- Phosphoproteins
- Wilms Tumor